Structure Therapeutics (GPCR) Competitors $20.62 +0.18 (+0.88%) Closing price 07/3/2025 03:10 PM EasternExtended Trading$20.62 +0.00 (+0.00%) As of 07/3/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. AKRO, ADMA, PCVX, KRYS, RYTM, CYTK, PTCT, ZLAB, ACAD, and MRUSShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Vaxcyte (PCVX), Krystal Biotech (KRYS), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), PTC Therapeutics (PTCT), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Its Competitors Akero Therapeutics ADMA Biologics Vaxcyte Krystal Biotech Rhythm Pharmaceuticals Cytokinetics PTC Therapeutics Zai Lab ACADIA Pharmaceuticals Merus Structure Therapeutics (NASDAQ:GPCR) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Which has more risk and volatility, GPCR or AKRO? Structure Therapeutics has a beta of -1.87, suggesting that its stock price is 287% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500. Do insiders and institutionals have more ownership in GPCR or AKRO? 91.8% of Structure Therapeutics shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, GPCR or AKRO? Akero Therapeutics is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$0.87-23.70Akero TherapeuticsN/AN/A-$252.06M-$1.95-26.67 Does the media refer more to GPCR or AKRO? In the previous week, Akero Therapeutics had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 5 mentions for Akero Therapeutics and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.51 beat Akero Therapeutics' score of 0.33 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer GPCR or AKRO? Structure Therapeutics presently has a consensus price target of $76.17, indicating a potential upside of 269.40%. Akero Therapeutics has a consensus price target of $82.50, indicating a potential upside of 58.61%. Given Structure Therapeutics' higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GPCR or AKRO more profitable? Akero Therapeutics' return on equity of -15.19% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.35% -15.71% Akero Therapeutics N/A -15.19%-13.97% SummaryStructure Therapeutics beats Akero Therapeutics on 8 of the 12 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.17B$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E Ratio-23.7021.5627.6520.23Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book1.377.538.035.65Net Income-$122.53M-$55.14M$3.18B$249.15M7 Day Performance-2.19%4.61%2.93%3.28%1 Month Performance-2.42%0.90%1.72%3.95%1 Year Performance-45.41%5.40%34.39%20.98% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.6704 of 5 stars$20.62+0.9%$76.17+269.4%-45.4%$1.17BN/A-23.70136AKROAkero Therapeutics3.4504 of 5 stars$53.36-5.0%$82.50+54.6%+142.5%$4.48BN/A-27.3630Insider TradeADMAADMA Biologics4.1503 of 5 stars$18.21+0.3%$27.67+51.9%+59.6%$4.34B$426.45M21.42530Positive NewsPCVXVaxcyte1.7706 of 5 stars$32.51-0.2%$136.50+319.9%-57.3%$4.20BN/A-8.15160News CoverageKRYSKrystal Biotech4.5831 of 5 stars$137.46-1.0%$211.13+53.6%-22.4%$4.01B$290.52M33.04210News CoverageAnalyst RevisionRYTMRhythm Pharmaceuticals3.8115 of 5 stars$63.19+0.7%$77.31+22.3%+55.6%$3.99B$130.13M-22.49140News CoverageCYTKCytokinetics3.9282 of 5 stars$33.04-0.4%$70.92+114.7%-38.9%$3.96B$18.47M-6.25250PTCTPTC Therapeutics4.3078 of 5 stars$48.84-2.0%$65.00+33.1%+57.7%$3.95B$806.78M7.501,410Analyst RevisionZLABZai Lab3.4092 of 5 stars$34.97+0.7%$54.28+55.2%+110.3%$3.86B$398.99M-14.041,869News CoverageInsider TradeAnalyst RevisionGap UpACADACADIA Pharmaceuticals4.6273 of 5 stars$21.57-2.5%$27.88+29.2%+29.9%$3.70B$957.80M15.74510MRUSMerus1.8266 of 5 stars$52.60-0.7%$84.64+60.9%+0.9%$3.67B$36.13M-12.8937 Related Companies and Tools Related Companies Akero Therapeutics Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Rhythm Pharmaceuticals Alternatives Cytokinetics Alternatives PTC Therapeutics Alternatives Zai Lab Alternatives ACADIA Pharmaceuticals Alternatives Merus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
